EXICURE, INC.
For the period ended Jun 30, 2025. Filed Aug 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 8, 2025
XCUR$1.08+21.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $389 | $(1,429) |
| Adjustments to reconcile net income (loss) to cash used in operating activities: | ||
| Depreciation and amortization | 132 | 14 |
| Equity-based compensation | 1 | 11 |
| Amortization of right-of-use asset | 104 | 390 |
| Change in fair value of contingent consideration | 295 | — |
| Gain on early lease termination | (5,974) | — |
| Gain on settlement of accounts payables | (191) | — |
| Loss from sale or disposal of property and equipment | 86 | — |
| Changes in operating assets and liabilities: | ||
| Other receivable | 1,434 | (544) |
| Prepaid expenses and other current assets | 169 | 415 |
| Other noncurrent assets | (734) | — |
| Accounts payable | 303 | (46) |
| Accrued expenses | 106 | (32) |
| Other liabilities | — | (395) |
| Net cash used in operating activities | (3,880) | (1,616) |
| Cash flows from investing activities: | ||
| Property and equipment | (320) | — |
| Proceeds from sale of fixed assets | 40 | — |
| Acquisition of GPCR Therapeutics USA Inc. | (2,090) | — |
| Net cash used in investing activities | (2,370) | — |
| Cash flows from financing activities: | ||
| Proceeds from short-term borrowing | — | 1,000 |
| Proceeds from common stock offering | 1,600 | — |
| Net cash provided by provided by financing activities | 1,600 | 1,000 |
| Net decrease in cash, cash equivalents, and restricted cash | (4,650) | (616) |
| Cash, cash equivalents, and restricted cash - beginning of period | 12,508 | 2,016 |
| Cash, cash equivalents, and restricted cash - end of period | $7,858 | $1,400 |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Supplemental disclosure of cash flow information | ||
| Non-cash investing activities: | ||
| Reclass prepaid expenses from noncurrent to current | $214 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.